Healx AI: Clinical Trials

4 completed, 1 terminated. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome OV101 - Angelman Syndrome	Phase 3	Terminated	Healx AI	141	2019-01-31	2025-07-18
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY) Soticlestat - 15q Duplication Syndrome, CDKL5 Deficiency Disease	Phase 2	Completed	Takeda	20	2018-09-10	2026-09-10
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Epilepsy, Dravet Syndrome	Phase 2	Completed	Takeda	141	2018-08-08	2026-09-14
Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies TAK-935, Placebo - Developmental and/or Epileptic Encephalopathies	Phase 1 / Phase 2	Completed	Takeda	18	2017-08-17	2026-09-14
A Study in Adults and Adolescents With Angelman Syndrome (STARS) OV101 Regimen 1, OV101 regimen 2, Placebo - Angelman Syndrome	Phase 2	Completed	Healx AI	88	2016-01-01	2025-08-03